Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience.

Christensen KD, Roberts JS, Royal CD, Fasaye GA, Obisesan T, Cupples LA, Whitehouse PJ, Butson MB, Linnenbringer E, Relkin NR, Farrer L, Cook-Deegan R, Green RC.

Genet Med. 2008 Mar;10(3):207-14. doi: 10.1097/GIM.0b013e318164e4cf.

3.

Apolipoprotein E and Alzheimer's disease: the implications of progress in molecular medicine.

Mayeux R, Schupf N.

Am J Public Health. 1995 Sep;85(9):1280-4. Review.

4.
5.

Susceptibility testing for Alzheimer's disease: race for the future.

Barber M, Whitehouse PJ.

Lancet Neurol. 2002 May;1(1):10. Review. No abstract available.

PMID:
12849539
6.

Understanding probabilistic risk in predisposition genetic testing for Alzheimer disease.

Koenig BA, Silverberg HL.

Genet Test. 1999;3(1):55-63. Review.

PMID:
10464578
7.

Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics.

Roberts JS, Christensen KD, Green RC.

Clin Genet. 2011 Nov;80(5):407-14. doi: 10.1111/j.1399-0004.2011.01739.x. Epub 2011 Jul 18. Review.

8.

Presymptomatic apolipoprotein E genotyping for Alzheimer's disease risk assessment and prevention.

Schipper HM.

Alzheimers Dement. 2011 Jul;7(4):e118-23. doi: 10.1016/j.jalz.2010.06.003. Epub 2011 Jun 14. Review.

PMID:
21665554
9.

Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues.

Roberts JS, Uhlmann WR.

Prog Neurobiol. 2013 Nov;110:89-101. doi: 10.1016/j.pneurobio.2013.02.005. Epub 2013 Apr 9. Review.

10.

Alzheimer's disease: clinical implications of the apolipoprotein E genotype.

Farlow MR.

Neurology. 1997 May;48(5 Suppl 6):S30-4. Review.

PMID:
9153158
11.

Apolipoprotein E, amyloid, and Alzheimer disease.

Bales KR, Dodart JC, DeMattos RB, Holtzman DM, Paul SM.

Mol Interv. 2002 Oct;2(6):363-75, 339. Review.

PMID:
14993413

Supplemental Content

Support Center